Global Hematology Diagnostic Devices And Equipment Market

Hemostasis is the process of slowing and stopping the blood flow to initiate wound healing after a vascular injury. With the help of hemostasis diagnostic devices, the cause of bleeding during surgery can be predicted by identifying any hemostatic defects in patients. The main products of hemostasis diagnostic devices and equipment are analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits. A hemostasis diagnostic analyzer is a tool utilised to predict the cause of bleeding during surgery by identifying any hemostatic defects. The hemostasis diagnostic devices and equipment are automated, semi-automated, and manual and are used by hospitals, clinics, independent diagnostic, laboratories, and others. The hemostasis diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides hemostasis diagnostic devices and equipment market statistics, including hemostasis diagnostic devices and equipment industry global market size, regional shares, competitors with a hemostasis diagnostic devices and equipment market share, detailed hemostasis diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis diagnostic devices and equipment industry. This hemostasis diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hemostasis diagnostic devices and equipment market size will grow from $4.77 billion in 2022 to $5.4 billion in 2023 at a compound annual growth rate (CAGR) of 13.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hemostasis diagnostic devices and equipment market size is expected to grow to $8 billion in 2027 at a CAGR of 10.3%. The increased likelihood of older people being diagnosed with a disease is driving the number of surgeries such as cardiovascular diseases (CVD), using hemostasis devices. Due to the higher incidence of diseases with advancing age, there is an increase in the number of surgeries in elderly patients nowadays. These hemostasis devices are very efficient in speeding up the natural process of clotting in the blood and can monitor anticoagulation and transfusion therapy guidance in any surgery. According to the American Heart Association report, Americans older than 80 have a high risk of devolving a cardiovascular disease (CVD), around 83% of men and 87.1% of females will be suffering from any form of CVD, therefore, to improve the comfort of the patient and the success rate of surgeries as a result hemostasis device has been implemented widely. The use of hemostasis devices in hospitals or clinics requires a very lengthy approval procedure which is restraining the market. Before hemostasis devices can enter the market for commercial use they have to clear the regulations set by the Code of Federal Regulations (title 21). The process of approval consists firstly identification of the device, secondly classification of the device and finally, the date of the pre-market approval (PMA) or the notice of completion of prescription drug plan (PDP) is required. It is a very long and time-consuming approval process that discourages new entrants from entering this market. For example, Cardiva medical Inc. had to wait for a processing period of four months before they received approval to change the existing equipment with a newer and modern one. The emergence of new and improved technology in the hemostasis diagnostic device and equipment market. To improve the quality and success rate of operations, new and improved technology such as the collagen vascular hemostasis devices have been implemented. Collagen is the main structural protein found in skin and other connective tissues. It is widely used in purified form for cosmetic surgical treatments and has now emerged in the hemostasis diagnostic devices market. A patient can face immobility right after a femoral surgery leading to increased discomfort, as a result, collagen-based closure devices have been implemented. According to a study conducted by the American Journal of Neuroradiology which they surveyed 698 Angio-Seal closures, using the Angio seal reduced the average time before mobilization by close to 15 minutes with no major complications. Angio seal is a type of collagen hemostasis device which reduces the average time of hemostasis and betters the mobilization of the patient. In 2021, Baxter International Inc., a leading global medical products company, has announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc for up to $60.8 million, as well as $25 million paid upfront. This acquisition helps the transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio. CryoLife, Inc. is one of the world's leading contemporary medical device companies. Major players in the hemostasis diagnostic devices and equipment market are C.R. Bard, Baxter International Inc., Pfizer Inc., Johnson & Johnson, Abbott Laboratories, Beckman Coulter Inc., Becton, Dickinson and Company, Chrono-Log Corporation, CSL Behring LLC, and F. Hoffmann-La Roche Ltd. North America was the largest region in the global hemostasis diagnostic devices and equipment market in 2022. Asia-Pacific was the second-largest region in the hemostasis diagnostic devices and equipment market. The regions covered in the global hemostasis diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hemostasis diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. Hemostasis diagnostic devices and equipment consists of sales of instruments such as analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits that are used in hemostasis diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hemostasis diagnostic devices and equipment market is segmented - 1) By Product: Analyzers, Coagulation Instrument, Other Hemostasis Instruments, Reagents and Kits 2) By End User: Hospitals, Clinics, Independent Diagnostic, Laboratories, Other End Users 3) By Device Technology: Automated, Semi-Automated, Manual

Hemostasis analyzers are devices that measure clotting mechanisms of hemostasis to detect clotting deficiencies. The natural ability of the body to stop bleeding quickly in order to stop serious blood loss is known as hemostasis. The main products in hemostasis analyzers are clinical laboratory analyzers, point-of-care testing analyzers, and consumables. The clinical laboratory analyzers are devices that are used to calculate the concentration of certain substances in various samples. The hemostasis analyzers are used to perform tests such as APTT tests, D dimer tests, platelet function tests, fibrinogen tests, prothrombin time tests, and other tests using optical technology, mechanical technology, electrochemical technology, and other technologies. The various end uses involved are hospitals and clinics, diagnostic centres, research and development organizations, ambulatory surgical centres, others. The hemostasis analyzers market research report is one of a series of new reports from The Business Research Company that provides hemostasis analyzers market statistics, including hemostasis analyzers industry global market size, regional shares, competitors with a hemostasis analyzers market share, detailed hemostasis analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis analyzers industry. This hemostasis analyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hemostasis analyzers market grew from $4.52 billion in 2022 to $4.84 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hemostasis analyzers market is expected to grow from $6.48 billion in 2027 at a CAGR of 7.5%. Increasing awareness regarding blood disorder conditions is driving the hemostasis analyzers market. Blood disorders such as Hemophilia and Von Willebrand disease (vWD) are genetic disorders and are not well known to people. This results in late diagnosis of blood disorders affecting the patients. For instance, the National Haemophilia Foundation's Red Tie Campaign is raising awareness about treatment for bleeding disorders like hemophilia, leukemia, myeloma, and lymphoma for approximately 3 million people in the USA with bleeding disorders. The Haemophilia Foundation Australia is an organization that is working towards the wellbeing of people affected by blood disorders through education, advocacy, and the promotion of research. Increasing awareness is expected to improve the diagnosis rate of blood disorders driving the demand for hemostasis analyzers. Recalls of defective hemostasis analyzers are acting as a restraint on the hemostasis analyzers market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hemostasis analyzer may provide wrong results and may cause misdiagnosis affecting consumer confidence in the analyzers. For instance, the U.S. Food and Drug Administration (FDA) recalled Siemens Healthcare Diagnostics, Inc’s automated hemostasis/ blood coagulation analyzer as the device was showing incorrect clotting time. The FDA recalled Fisher Diagnostics’ hemostasis kit due to sensitivity issues. Product recalls severely affect the revenues of manufacturers, acting as a restraint on the market. Manufacturers of hemostasis analyzers are investing in the research and development of portable, handheld hemostasis analyzers which are convenient to be carried anywhere and are small enough to fit in a person's palm. These portable hemostasis analyzers provide a faster and easier testing process and facilitate independent analysis of results instead of having to visit a diagnostic center. For instance, Siemens Healthcare offers the Xprecia Stride Coagulation Analyzer which is small enough to fit inside a pocket and provides accurate results. Also, the Coatron coagulation analyzer by TECO Medical Instruments is a portable, handheld semi-automatic hemostasis analyzer. Manufacturers of hemostasis analyzers are governed by regulatory bodies such as the Food and Drug Administration (FDA) in the USA. The FDA has classified hemostasis analyzers into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post-market surveillance, and labeling requirements associated with device usage. The labeling of hemostasis analyzers is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before the equipment is released into the market. Major players in the hemostasis analyzers market are Thermo Fisher Scientific Inc., Alere Inc., Siemens AG, F-Hoffmann La Roche, Nihon Kohden Corporation, Sysmex Corporation, Helena Laboratories, International Technidyne Corporation, Instrumentation Laboratory (A Division of the Werfen Group), and Abbott. North America was the largest region in the hemostasis analyzers market in 2022. Western Europe was the second largest region in the global hemostasis analyzers market report. The regions covered in the global hemostasis analyzers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hemostasis analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The hemostasis analyzers market consists of sales of complete blood count (CBC), factor v assay, fibrinogen level, prothrombin time (PT or PT-INR), platelet count, and thrombin time. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hemostasis analyzers market is segmented - 1) By Product: Clinical Laboratory Analyzers, Point-Of-Care Testing Analyzers, Consumables 2) By End Use: Hospitals & Clinics, Diagnostic Centers, Research And Development Organisations, Ambulatory Surgical Centers, Other End Uses 3) By Test: APTT Tests, D Dimer Tests, Platelet Function Tests, Fibrinogen Tests, Prothrombin Time Tests, Other Tests 4) By Technology: Optical Technology, Mechanical Technology, Electrochemical Technology, Other Technologies

Autoimmune diseases diagnosis are the diseases in which the production of antibodies takes place in the body which attacks and destroys own healthy cells in the body. These include Crohn's disease, rheumatoid arthritis, Hashimoto’s disease, multiple sclerosis, Grave’s disease, psoriasis, coeliac disease, type 1 diabetes, lupus and inflammatory bowel syndrome, and are diagnosed by immunological tests. The main test types of autoimmune disease diagnosis are routine laboratory tests, autoantibodies tests, immunologic tests, and other tests. Autoantibody tests are used to aid in the diagnosis of autoimmune diseases. The different products include consumables and assay kits, instruments and are used by various sectors such as clinical laboratories, hospitals, and others. The autoimmune disease diagnosis market research report is one of a series of new reports from The Business Research Company that provides autoimmune disease diagnosis market statistics, including autoimmune disease diagnosis industry global market size, regional shares, competitors with a autoimmune disease diagnosis market share, detailed autoimmune disease diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune disease diagnosis industry. This autoimmune disease diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global autoimmune disease diagnosis market size will grow from $5.15 billion in 2022 to $5.56 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global autoimmune disease diagnosis market size is expected to grow to $7.55 billion in 2027 at a CAGR of 8.0%. A high incidence of autoimmune diseases contributed to the growth of the autoimmune disease diagnosis market. According to the Autoimmune Registry Inc. (ARI) first comprehensive list of Autoimmune Diseases published in 2020, between 15 and 30 million people in the United States suffer from autoimmune disease, making it the nation's largest class of illness, and it primarily affects women aged 20 to 40. Therefore, increasing incidence of autoimmune diseases across the globe is driving the autoimmune disease diagnosis market. The high cost of diagnostic tests is a major challenge for the growth of the autoimmune disease diagnosis market. According to a survey by the National Adrenal Diseases Foundation (NADF), the cost for initial diagnosis of Addison’s disease is $1,680 per patient and according to the reports of Vasculitis Foundation of America, vasculitis affects 1 in 20 Americans and the total cost for vasculitis patient per year is $9.7 billion. According to the estimations of The National Institutes of Allergy and Infectious Diseases (NIAID), the annual cost of treating an autoimmune disease in the US is greater than $100 billion and says that annual direct and indirect cost to treat rheumatoid arthritis in the US is $10.9 billion and $8.4 billion respectively. The high cost of diagnosis is increasing the cost burdens on the patients impacting the growth of the autoimmune disease diagnosis market Biosensors and nano biosensors for rapid detection is a novel tool for the detection of antibodies in the autoimmune disease diagnosis market. They are highly preferred because of low cost, high sensitivity, simple to use, multiplexing abilities and rapid diagnosis. Besides measuring the quantity of antibodies in human blood serum with extremely high sensitivity, it also quantifies the activity of antibodies as the assay employs portable optical label-free biosensors based on the spectral correlation interferometry. This point of care technology gives a more integrated, informative, timely and precise diagnosis of autoimmune diseases when compared to the conventional ones. Major players in the autoimmune disease diagnosis market are Thermo Fisher Scientific, Siemens Healthineers, Abbott, Danaher, Bio-Rad Laboratories, Trinity Biotech, HYCOR Biomedical, EUROIMMUN AG, AESKU GROUP GMBH & CO. KG and F. Hoffmann-La Roche Ltd. North America was the largest region in the autoimmune disease diagnosis market in 2022. Western Europe was the second largest region in the global autoimmune disease diagnosis market. The regions covered in the global autoimmune disease diagnosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the autoimmune disease diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The autoimmune disease diagnosis market includes revenue earned by diagnostic assay kits, reagents, consumables and instruments used for the diagnosis of autoimmune diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global autoimmune disease diagnosis market is segmented - 1) By Product: Consumables & Assay Kits, Instruments 2) By Test Type: Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests, Other Tests 3) By End User: Clinical Laboratories, Hospitals, Other End Users

Alpha mannosidosis refers to a rare genetic disorder defined by the body's cells' inability to adequately break down specific groups of complex sugars. Numerous bodily organs and systems, including the central nervous system, are impacted by sugar buildup. The disease's effects might vary greatly from person to person. The main types of therapy for alpha mannosidosis are bone marrow transplant (BMT), enzyme replacement therapy (ERT), peripheral blood stem cell transplantation (PBSCT) and gene therapy. A bone marrow transplant is a procedure in which dysfunctional marrow is replaced with healthy marrow. Enzyme replacement therapy includes replacing a defective enzyme in people who are lacking or deficient in that enzyme. Peripheral blood stem cell transplantation is a procedure in which the patient whose stem cells have been destroyed by disease or by radiation or high doses of anticancer drugs, receives healthy stem cells. Gene therapy is a procedure in which DNA is introduced to a patient to treat a genetic disease. The different types of indications include Type I, Type II and Type III and are implemented in a wide range of verticals such as hospitals and speciality clinics. The alpha mannosidosis market research report is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with a alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global alpha mannosidosis market size grew from $10.59 billion in 2022 to $12.65 billion in 2023 at a compound annual growth rate (CAGR) of 19.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The alpha mannosidosis market size is expected to grow to $24.27 billion in 2027 at a CAGR of 17.7%. The increasing investments in research are expected to contribute to the growth of the alpha mannosidosis market in the forecast period. Currently, in the alpha mannosidosis market, only one company has therapies for rare genetic diseases. However, several firms have products in the clinical stages, which will boost market demand in the forecast period. For instance, in 2020, the EU clinical trials database lists 39,219 clinical trials with a EudraCT protocol, 6,426 of which are clinical trials involving subjects under the age of 18. Therefore, the increasing investments in research fuel the growth of the alpha mannosidosis market. The advancements in treatment for alpha mannosidosis like pharmacological therapy are gaining traction in the alpha mannosidosis market. For instance, in 2018 – Chiesi Group, an international research-focused Healthcare company, announced that it has received a positive opinion recommending the marketing authorization of Velmanase Alfa, under the brand name Lamzede from the European Medicines Agency Committee for Medicinal Products for Human Use. Lamzede is an enzyme replacement therapy intended to provide or supplement natural alpha-mannosidase, an enzyme that helps with the degradation of mannose–rich oligosaccharides and thus prevents their accumulation in various tissues in the body. Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex. North America was the largest region in the alpha mannosidosis market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global alpha mannosidosis market is segmented - 1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy 2) By Indication: Type I, Type II, Type III 3) By End-User: Hospitals, Speciality Clinics

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

Haematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in haematology analyzers and reagents are haematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and haematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The haematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides haematology analyzers and reagents market statistics, including haematology analyzers and reagents industry global market size, regional shares, competitors with a haematology analyzers and reagents market share, detailed haematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the haematology analyzers and reagents industry. This haematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology analyzers and reagents market grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology analyzers and reagents market is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. Major players in the haematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. North America was the largest region in the haematology analyzers market in 2022. Western Europe was the second largest region in the global haematology analyzers market report. The regions covered in the global haematology analyzers and reagents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the haematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The haematology analyzers market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global haematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users

The vascular grafts are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular grafting or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process improves the blood flow by redirecting blood from one area of the body to another. The main products of the vascular graft are hemodialysis access graft, endovascular stent graft, peripheral vascular graft, and coronary artery bypass graft. Endovascular stent graft refers to the method of minimally invasive method that is used to treat an aortic aneurysm and is performed to know the presence of abdominal pain, symptoms for the disease, and also for the size of the aneurysm. The various raw materials are polyester grafts, ePTFE, polyurethane grafts, and biosynthetic grafts. The various applications of vascular graft are coronary artery disease, aneurysm, vascular occlusion, and renal failure that are used by end-users such as hospitals and ambulatory surgical centres. The vascular graft market research report is one of a series of new reports from The Business Research Company that provides vascular graft market statistics, including vascular graft industry global market size, regional shares, competitors with a vascular graft market share, detailed vascular graft market segments, market trends and opportunities, and any further data you may need to thrive in the vascular graft industry. This vascular graft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global vascular grafts market grew from $2.96 billion in 2022 to $3.21 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vascular grafts market is expected to grow from $4.37 billion in 2027 at a CAGR of 8.1%. The rising prevalence of vascular diseases is driving the growth of the global vascular grafts market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world and according to the American Heart Association (AHA), the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market. The high cost of medical treatment and complications related to prosthetic grafts are expected to restrain global vascular grafts market growth. The cost of the CABG (coronary artery bypass graft) surgery is very high in western countries. For instance, in the US, the average cost of coronary artery bypass surgery is $40,000, which varies widely by region and facility. Moreover, several complications are associated with prosthetic grafts such as disruption of an infected anastomotic suture line due to rupture or pseudoaneurysm formation, sepsis, amputation, thromboembolism, chances of reinfection due to vascular grafts reconstruct, enteric fistulae, the spread of bacterial infection to other sites, and death. Thus, high treatment costs and complications related to prosthetic grafts are expected to restrain the market growth. Companies in the vascular graft market are increasingly investing in technological advances for the development of innovative vascular grafts, including customization of vascular grafts. For instance, RelayPro, a thoracic stent graft system recently launched by Terumo Aortic, is a low-profile device designed for patients with smaller access vessels in the treatment of thoracic endovascular aortic repair (TEVAR). It offers a broad range of diameters, lengths, tapers, and proximal configurations to the physicians. Both bare stent and non-bare stent (NBS) versions are available for this device and they can be customized to meet the patient’s specific anatomical needs. In June 2020, LeMaitre Vascular, a US-based medical device company, acquired Artegraft for $90 million. The acquisition the company expected to extend its product line with Artegraft’s innovative products and better serve the customers’ needs. Artegraft is a New Jersey-based seller of vascular grafts. Major players in the vascular graft market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic PLC., Getinge, Terumo Medical Corporation, and Gore Medical. North America was the largest region in the vascular graft market in 2022. Western Europe was the second largest region in the global vascular graft market report. The regions covered in the global vascular graft market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vascular graft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The vascular grafts market consists of sales of polytetrafluoroethylene (Teflon), polyethylene terephthalate (Dacron), or a different person's vein (allograft). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global vascular grafts market is segmented - 1) By Product: Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft 2) By Raw Material: Polyester Grafts, ePTFE, Polyurethane Grafts, Biosynthetic Grafts 3) By Application: Coronary Artery Disease, Aneurysm, Vascular Occlusion, Renal Failure 4) By End-User: Hospitals, Ambulatory Surgical Centers

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases. This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma. It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots. The main types of hermatology drugs are blood products, anemia and other blood disorder drugs. Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood components for transfusion as well as plasma-derived medicinal products. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global hematology drugs market size is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology drugs market is expected to reach $73.67 billion in 2026 at a CAGR of 19.5%. The hematology drugs market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) stated that the global GDP growth rate was 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. This is expected to increase spending on healthcare services, thereby driving the demand for hematology drugs. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the hematology drugs industry in the historic period. Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its low price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. According to the World Maternal Antifibrinolytic (WOMAN) trial, using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%. The trial included over 20,000 women from 193 hospitals in 21 countries. Major companies in the hematology market include Amgen, Alexion Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd., CSL, Takeda Pharmaceuticals, Novo Nordisk, Sanofi S.A, Daiichi Sankyo Company and Pfizer Inc. North America was the largest region in the hematology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the hematology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global hematology drugs market is segmented - 1) By Type: Blood Products, Anemia and Other Blood Disorder Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs